Back to Journals » International Journal of Nanomedicine » Volume 7

Noninvasive near-infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson’s disease

Authors Bossolasco P, Cova L , Levandis, Diana V, Cerri, Deliliers GL, Polli, Silani V, Blandini F, Armentero M

Received 22 October 2011

Accepted for publication 16 November 2011

Published 31 January 2012 Volume 2012:7 Pages 435—447

DOI https://doi.org/10.2147/IJN.S27537

Review by Single anonymous peer review

Peer reviewer comments 2



P Bossolasco1,*, L Cova2,*, G Levandis3, V Diana2, S Cerri3, G Lambertenghi Deliliers1, E Polli1, V Silani2,4, F Blandini3, MT Armentero3
1
Fondazione Matarelli, Dipartimento di Farmacologia, Chemioterapia e Tossicologia Medica, Università degli Studi di Milano, Milan, 2Department of Neurology and Laboratory of Neuroscience-IRCCS Istituto Auxologico Italiano, Cusano Milanino, 3Laboratory of Functional Neurochemistry, Interdepartmental Research Centre for Parkinson’s Disease, IRCCS National Institute of Neurology “C Mondino”, Pavia, 4Department of Neurology and Laboratory of Neuroscience, Centro “Dino Ferrari” Università degli Studi di Milano-IRCCS Istituto Auxologico Italiano, Milan, Italy
*These authors contributed equally to this work

Background: We have previously shown that human mesenchymal stem cells (hMSCs) can reduce toxin-induced neurodegeneration in a well characterized rodent model of Parkinson’s disease. However, the precise mechanisms, optimal cell concentration required for neuroprotection, and detailed cell tracking need to be defined. We exploited a near-infrared imaging platform to perform noninvasive tracing following transplantation of tagged hMSCs in live parkinsonian rats.
Methods: hMSCs were labeled both with a membrane intercalating dye, emitting in the near-infrared 815 nm spectrum, and the nuclear counterstain, Hoechst 33258. Effects of near-infrared dye on cell metabolism and proliferation were extensively evaluated in vitro. Tagged hMSCs were then administered to parkinsonian rats bearing a 6-hydroxydopamine-induced lesion of the nigrostriatal pathway, via two alternative routes, ie, intrastriatal or intranasal, and the cells were tracked in vivo and ex vivo using near-infrared technology.
Results: In vitro, NIR815 staining was stable in long-term hMSC cultures and did not interfere with cell metabolism or proliferation. A significant near-infrared signal was detectable in vivo, confined around the injection site for up to 14 days after intrastriatal transplantation. Conversely, following intranasal delivery, a strong near-infrared signal was immediately visible, but rapidly faded and was completely lost within 1 hour. After sacrifice, imaging data were confirmed by presence/absence of the Hoechst signal ex vivo in coronal brain sections. Semiquantitative analysis and precise localization of transplanted hMSCs were further performed ex vivo using near-infrared imaging.
Conclusion: Near-infrared technology allowed longitudinal detection of fluorescent-tagged cells in living animals giving immediate information on how different delivery routes affect cell distribution in the brain. Near-infrared imaging represents a valuable tool to evaluate multiple outcomes of transplanted cells, including their survival, localization, and migration over time within the host brain. This procedure considerably reduces the number of animal experiments needed, as well as interindividual variability, and may favor the development of efficient therapeutic strategies promptly applicable to patients.

Keywords: 6-hydroxydopamine, intranasal, intrastriatal, neurodegeneration, cell tracking

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.